About UCB
UCB is a company based in Brussels (Belgium) founded in 1928.. UCB has completed 8 acquisitions, including Be4, Element Genomics and Engage Therapeutics. UCB operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Brussels, Belgium
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$301.94 K (USD), Grant
Jan 01, 2020
-
Investors
European Union
& 1 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Be4
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Software Development Team
219 people
Leadership Team
92 people
Head Team
57 people
Global Team
39 people
Senior Team
36 people
Operations Team
36 people
Product Management Team
34 people
Human Resources and Administration
22 people
Unlock access to complete
Funding Insights of UCB
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $301,942
-
First Round
First Round
(22 Dec 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Grant - UCB | Valuation |
investors |
|
| Feb, 2016 | Amount | Grant - UCB | Valuation |
investors |
|
| Jan, 2016 | Amount | Grant - UCB | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in UCB
UCB has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Paul Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Functions as a diversified investor in secondary markets.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by UCB
UCB has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Be4, Element Genomics and Engage Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapy to treat neurodegenerative diseases
|
2019 | ||||
|
Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures
|
2017 | ||||
|
An epigenomic editing platform is developed to identify drug targets.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - UCB
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ucb Comparisons
Competitors of UCB
UCB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ucb
Frequently Asked Questions about UCB
When was UCB founded?
UCB was founded in 1928 and raised its 1st funding round 81 years after it was founded.
Where is UCB located?
UCB is headquartered in Brussels, Belgium. It is registered at Brussels, Brussels-capital Region, Belgium.
What does UCB do?
UCB was founded in 1928 and is headquartered in Brussels, Belgium. Focus is placed on the pharmaceutical sector, where therapies for immunological and neurological disorders are developed. Operations encompass the creation and distribution of medications such as Briviact, Vimpat, and Keppra for epilepsy treatment; Neupro for Parkinsons disease; and Cimzia for rheumatoid arthritis. Additional products are maintained in the portfolio to address related conditions globally.
Who are the top competitors of UCB?
UCB's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
How many acquisitions has UCB made?
UCB has made 8 acquisitions, including Be4, Element Genomics, and Engage Therapeutics.
Who are UCB's investors?
UCB has 2 investors. Key investors include European Union, and Paul Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.